D V Jones Jr
Overview
Explore the profile of D V Jones Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravindranathan M, Klementich F, Jones Jr D
Leukemia
. 2007 Jul;
21(12):2546-7.
PMID: 17657221
No abstract available.
2.
Wolff S, Herzig R, Lynch J, Ericson S, Greer J, Stein R, et al.
Bone Marrow Transplant
. 2001 Mar;
27(3):261-8.
PMID: 11277173
Thrombocytopenia following myelotoxic therapy is a common problem and when severe (<20,000/microl) can lead to severe morbidity and mortality. Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the...
3.
Jones Jr D, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, et al.
Stem Cells
. 2000 Sep;
16 Suppl 2:199-206.
PMID: 11012192
Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions....
4.
Osborne C, LeBoeuf H, Jones Jr D
Ann Intern Med
. 2000 Jun;
132(12):1007.
PMID: 10858163
No abstract available.
5.
Patt Y, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, et al.
J Clin Oncol
. 1997 Apr;
15(4):1432-8.
PMID: 9193336
Purpose: To determine the toxicity, response rate, and survival in patients treated with hepatic arterial infusion (HAI) of fluorouracil (5-FU) plus recombinant human interferon alfa-2b (rIFN-alpha 2b) (Intron-A; Schering-Plough, Inc,...
6.
Jones Jr D, Wu E, Manire M, Frazier M
Gastroenterology
. 1997 Mar;
112(3):776-82.
PMID: 9041239
Background & Aims: The nonspecific cross-reacting antigen (NCA) is a cell adhesion molecule, and the messenger RNA for NCA is overexpressed in 92% of colorectal carcinomas. The aim of this...
7.
Patt Y, Jones Jr D, Hoque A, Lozano R, Markowitz A, Raijman I, et al.
J Clin Oncol
. 1996 Aug;
14(8):2311-5.
PMID: 8708722
Purpose: To assess the efficacy of systemic intravenous-fluorouracil (5-FU) and subcutaneous recombinant human interferon alfa-2b (rIFN alpha-2b) in patients with measurable cancer of the biliary tree. Patients And Methods: Thirty-five...
8.
Jones Jr D, Lozano R, Hoque A, Markowitz A, Patt Y
J Clin Oncol
. 1996 Aug;
14(8):2306-10.
PMID: 8708721
Purpose: To evaluate the efficacy of paclitaxel administered to patients with unresectable adenocarcinomas of the gallbladder and biliary tree over 3 hours every 21 days. Patients And Methods: Fifteen patients...
9.
Jones Jr D, Winn R, BROWN B, Levy L, PUGH R, Wade 3rd J, et al.
Cancer
. 1995 Nov;
76(10):1709-14.
PMID: 8625038
Background: Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil (5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea...
10.
Jones Jr D, LAWRENCE D, Patt Y
Ann Intern Med
. 1995 Nov;
123(10):810-1.
PMID: 7574209
No abstract available.